TRIP12 and ovarian cancer: Strikingly, TRIP12 depletion strongly sensitized FBW7 wild type ovarian cancer cells whereas FBW7R505L mutant cell line was resistant to Taxol treatment regardless of TRIP12 status (Figure 6A–C).